(Q38352874)

2 September 2017

1 reference

title

Genitourinary small cell malignancies: prostate and bladder (English)

1 reference

2 September 2017

Michael O Koch

1 reference

2 September 2017

Kashyap Shatagopam

1 reference

2 September 2017

Hristos Z Kaimakliotis

series ordinal

1 reference

2 September 2017

Liang Cheng

series ordinal

1 reference

2 September 2017

language of work or name

English

0 references

publication date

1 January 2015

1 reference

2 September 2017

1 reference

2 September 2017

1 reference

2 September 2017

1 reference

2 September 2017

page(s)

479-488

1 reference

Small cell carcinoma of the bladder and prostate

2 September 2017

cites work

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.277

Medical Research Council comparative trial of surgery and radiotherapy for primary treatment of small-celled or oat-celled carcinoma of bronchus. Ten-year follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.277

Genitourinary small cell carcinoma: determination of clinical and therapeutic factors associated with survival

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.277

Neuroendocrine tumours of the urinary system and male genital organs: clinical significance

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.277

Small cell carcinoma of the prostate. A morphologic and immunohistochemical study of 95 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.277

Small cell carcinoma of the urinary bladder: a rare, aggressive neuroendocrine malignancy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.277

Genitourinary small cell carcinoma: a retrospective review of treatment and survival patterns at The Ottawa Hospital Regional Cancer Center

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.277

Phase II clinical trial of neoadjuvant alternating doublet chemotherapy with ifosfamide/doxorubicin and etoposide/cisplatin in small-cell urothelial cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.277

The new World Health Organization classification of lung tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.277

Small cell carcinoma of the prostate: an immunohistochemical study.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.277

A clinical review of small-cell carcinoma of the urinary bladder

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.277

TMPRSS2-ERG gene fusion in small cell carcinoma of the prostate.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.277

Small-cell carcinoma of the urinary bladder: diagnosis and management

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.277

Unusual and underappreciated: small cell carcinoma of the prostate.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.277

Ectopic ACTH, prostatic oat cell carcinoma, and marked hypernatremia

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.277

Results of a phase II study with doxorubicin, etoposide, and cisplatin in patients with fully characterized small-cell carcinoma of the prostate

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.277

Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.277

Use of irinotecan for treatment of small cell carcinoma of the prostate

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.277

Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.277

Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.277

Small cell carcinoma of bladder: a single-center prospective study of 25 cases treated in analogy to small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.277

Should histologic variants alter definitive treatment of bladder cancer?

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.277

Small cell carcinoma of the urinary bladder. A clinicopathologic, morphometric, immunohistochemical, and ultrastructural study of 18 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.277

Small cell carcinoma of the urinary bladder. The Mayo Clinic experience

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.277

Evidence supporting preoperative chemotherapy for small cell carcinoma of the bladder: a retrospective review of the M. D. Anderson cancer experience.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.277

Long-term survival after sequential chemoradiation for limited disease small cell carcinoma of the bladder

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.277

Local control rate and prognosis after sequential chemoradiation for small cell carcinoma of the bladder.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.277

Small cell lung cancer: therapies and targets

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.277

Rb loss is characteristic of prostatic small cell neuroendocrine carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.277

Small Cell (Neuroendocrine) Carcinoma of the Prostate: Etiology, Diagnosis, Prognosis, and Therapeutic Implications—A Retrospective Study of 30 Patients From the Rare Cancer Network

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.277

21 January 2018

Identifiers

DOI

10.2217/FON.14.277

1 reference

2 September 2017

1 reference